Close Menu
  • Home
  • Economic News
  • Stock Market
  • Real Estate
  • Crypto
  • Investment
  • Personal Finance
  • Retirement
  • Banking

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

68 Jobs Qualify for ‘No Tax on Tips’ — Is Yours One of Them?

September 2, 2025

British Comedy Writer Arrested For Three Gender-Critical Tweets; Hospitalized As A Result

September 2, 2025

Sales comparison approach: A guide for home sellers

September 2, 2025
Facebook X (Twitter) Instagram
  • Contact Us
  • Privacy Policy
  • Terms Of Service
Tuesday, September 2
Doorpickers
Facebook X (Twitter) Instagram
  • Home
  • Economic News
  • Stock Market
  • Real Estate
  • Crypto
  • Investment
  • Personal Finance
  • Retirement
  • Banking
Doorpickers
Home»Stock Market»These Stock Winners Are ‘Strong Buys’ With More Room Left to Run
Stock Market

These Stock Winners Are ‘Strong Buys’ With More Room Left to Run

July 17, 2024No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

The past year saw a strong bull market, and this year stocks are still on a winning streak. The NASDAQ has seen a 30% gain over the last 12 months, while the S&P 500 index is up 25% over the same period. Investors are now looking for solid choices with more potential for growth.

While the typical strategy is to buy low and sell high, there are also opportunities in stocks that have already shown strong performance in recent months. These stocks may still have room for further growth despite their current high levels.

Wall Street analysts are focusing on stocks that have shown triple-digit percentage gains in the last year and are still performing well. Two such stocks with a Strong Buy consensus rating are Soleno Therapeutics (SLNO) and MoneyLion (ML).

Soleno Therapeutics is a biopharma company working on new drug candidates for rare genetic diseases. The company’s leading candidate, DCCR, has shown promising results in clinical trials for Prader-Willi Syndrome. Analysts are optimistic about the potential approval of DCCR, with a price target of $72, representing a 40% upside potential for SLNO shares.

MoneyLion is a fintech company in the personal banking sector, catering to the average American consumer. The company offers a range of financial services and saw a 98% increase in customers in the first quarter of 2024. Analysts believe that MoneyLion’s execution and growth potential make it an attractive investment, with a price target of $109, implying a 25% upside for ML shares.

Both stocks have received unanimous positive analyst reviews and have a Strong Buy consensus rating. Soleno Therapeutics has a $70.75 average price target, while MoneyLion has a $114 average price target, suggesting gains of 37% and 31%, respectively, over the next year.

For more stock ideas, visit TipRanks’ Best Stocks to Buy tool. Please note that the opinions expressed in this article are those of the featured analysts and should be used for informational purposes only. Conduct your own analysis before making any investment decisions.

Buys Left Room Run Stock Strong winners
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Will the stock market crash in 2025? Watch these 3 key indicators carefully

August 31, 2025

Jack Dorsey’s Bitchat wants your neighborhood to run on Bitcoin

August 31, 2025

Argentina Pioneers Stock Tokenization Under Regulatory Sandbox

August 27, 2025
Add A Comment
Leave A Reply Cancel Reply

Top Posts

How to get free stocks: 6 ways to earn free shares

July 27, 20250 Views

US to probe Chinese telecom groups it suspects of posing security risk

March 21, 20251 Views

Stock Futures Falling as Market Weighs Economic Data, Tariff Fears

March 18, 20250 Views
Stay In Touch
  • Facebook
  • YouTube
  • TikTok
  • WhatsApp
  • Twitter
  • Instagram
Latest
Personal Finance

68 Jobs Qualify for ‘No Tax on Tips’ — Is Yours One of Them?

September 2, 20250
Economic News

British Comedy Writer Arrested For Three Gender-Critical Tweets; Hospitalized As A Result

September 2, 20250
Real Estate

Sales comparison approach: A guide for home sellers

September 2, 20250
Facebook X (Twitter) Instagram Pinterest
  • Contact Us
  • Privacy Policy
  • Terms Of Service
© 2025 doorpickers.com - All rights reserved

Type above and press Enter to search. Press Esc to cancel.